Mental Health Gap Action Programme (mhGAP) Guideline for Mental, Neurological and Substance Use Disorders.

Format:

Book

Author/Creator:

World Health Organization, author, issuing body.

Language:

English

Subjects (All):

Mental health services.

Physical Description:

1 online resource (184 pages)

Edition:

1st ed.

Place of Publication:

Geneva : World Health Organization, 2023.

Summary:

The Mental Health Gap Action Programme (mhGAP) guideline, published by the World Health Organization in 2023, provides comprehensive strategies for addressing mental, neurological, and substance use disorders. The guideline aims to improve mental health care by offering evidence-based recommendations for health settings. It serves as an update to previous editions from 2010 and 2015, reflecting the latest research and practices in global mental health. The guideline is targeted at healthcare providers, policymakers, and organizations involved in mental health services. Its purpose is to bridge the gap in mental health treatment by enhancing accessibility and quality of care worldwide. Generated by AI.

Contents:

Acknowledgements

Abbreviations

Glossary

Executive summary

1. Introduction

1.1. Background and rationale

1.2. Aims and objectives

1.3. Target audience

1.4. Scope of the guideline

2. Methods

2.1. Contributors to the guideline

2.2. Declaration of interests

2.3. Identifying, appraising and synthesizing available evidence

2.4. Decision-making during the GDG meetings

2.5. Document preparation and peer review

3. Recommendations

3.1. Alcohol use disorders (ALC)

3.2. Anxiety (ANX)

3.3. Child and adolescent mental disorders (CAMH)

3.4. Conditions related to stress (STR)

3.5. Dementia (DEM)

3.6. Depression (DEP)

3.7. Drug use disorders (DRU)

3.8. Epilepsy and seizures (EPI)

3.9. Overarching areas (OVE)

3.10. Psychosis and bipolar disorder (PSY)

3.11. Self-harm and suicide (SUI)

4. Publication

4.1. Publication and dissemination of the guideline

4.2. Derivative products

4.3. WHO model list of essential medicines (EML)

5. Monitoring and evaluating the impact of the guideline

6. Updating the evidence

References

Annex 1. Contributors to the guideline

Annex 2. Managing declarations of interest and conflicts of interest.

Notes:

Description based on publisher supplied metadata and other sources.

Part of the metadata in this record was created by AI, based on the text of the resource.

Other Format:

Print version: Mental Health Gap Action Programme (mhGAP) Guideline for Mental, Neurological and Substance Use Disorders

ISBN:

9789240084278

OCLC:

1450107102